|Articles|June 27, 2023
Opioid Reformulation for Abuse Deterrence - Filed as a CMC Supplement in Less Than a Year
Author(s)Societal CDMO
It is no secret that Opioid abuse is an ongoing public health emergency. Societal™’s client stood at an impasse in pursuit of providing pain relief to patients, while following the recommendation of the FDA to reformulate the product for abuse deterrence.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
2
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
3
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence
4
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
5